AI‑Stroke Raises $4.6M Seed to Advance AI-Powered Pre-Hospital Stroke Diagnostics

AI‑Stroke, a French MedTech startup developing AI‑powered pre‑hospital stroke diagnostics, has raised $4.6 million in a seed funding round to advance its technology for faster, more accurate stroke triage before conventional imaging is available. The financing round — completed in late 2025 — underscores investor confidence in AI‑Stroke’s AI‑based approach to supporting emergency medical services personnel and improving early stroke detection, a critical factor in reducing long‑term disability and death from strokes.

The seed round was led by Heka, the BrainTech‑focused investment vehicle of Newfund VC, and included participation from prominent angel investors as well as backing from Bpifrance. These investors bring a mix of sector‑specific expertise and strategic capital as AI‑Stroke prepares for clinical validation and regulatory progress.

Founded in 2022 by a team of engineers, physicians, and former investors, AI‑Stroke is building what it terms an “AI neurologist” — a software‑as‑a‑medical‑device solution designed to support emergency responders and clinicians with rapid stroke assessment. The company’s flagship product turns a standard smartphone or tablet into a rapid stroke triage tool: first responders record a 30‑second video of a patient performing guided movements and speech exercises, and the artificial intelligence system instantly analyses facial symmetry, arm motion, and speech patterns to detect signs consistent with a stroke. This pre‑CT assessment is intended to guide early decision‑making before more resource‑intensive imaging is available.

The startup’s technology has been trained on an extensive proprietary dataset — including more than 20,000 videos and six million images — allowing its algorithms to learn patterns associated with stroke symptoms and outperform traditional visual assessments in certain real‑world conditions. In testing involving more than 2,000 emergency medical service personnel, AI‑Stroke’s system demonstrated superior true‑positive detection rates compared with standard recognition approaches, which often rely on subjective interpretation or less systematic methods.

The $4.6 million in new capital will support AI‑Stroke’s upcoming FDA regulatory pathway and the launch of multi‑site clinical studies across leading U.S. stroke centers, marking a transition from early development to broader clinical validation. This step is critical as the company pursues adoption in markets with stringent regulatory requirements and widespread demand for improved pre‑hospital stroke care tools.

Stroke remains one of the leading causes of death and disability worldwide, with rapid diagnosis and treatment being crucial to preserving brain function. Delays in recognition — particularly in pre‑hospital settings — often result in patients missing narrow treatment windows for interventions like thrombolytic therapy or mechanical thrombectomy. AI‑Stroke’s vision is to help close this gap by equipping first responders with an accessible, fast, data‑driven diagnostic aid to inform decisions that can significantly impact patient outcomes.

CEO and co‑founder Cédric Javault and his team have focused not only on algorithmic performance but also on practical usability and integration into emergency workflows. The tool’s smartphone‑based nature means it requires no special hardware beyond devices already in use by many first responders, lowering barriers to adoption and enabling rapid deployment across EMS teams.

Beyond the core emergency use case, the startup’s technology also holds potential for expanding stroke assessment capabilities in areas with limited access to advanced imaging facilities. By providing objective, AI‑enhanced evaluation before patients reach a hospital, AI‑Stroke seeks to reduce the burden of stroke diagnosis on healthcare systems and improve equity in access to fast, high‑quality care.

AI‑Stroke’s seed funding round follows its earlier development milestones, including initial private investment and early product refinement. The backing from Heka, Bpifrance, and angel investors positions the company to scale its team, engage in rigorous clinical validation, and pursue regulatory clearances essential for broader commercialisation.

With its proprietary dataset and AI‑based diagnostic engine, AI‑Stroke is aiming to set a new standard for pre‑hospital stroke triage — a space where time is literally brain, and improved early detection can save thousands of lives and reduce long‑term disability globally. Supported by its seed funding and strategic partnerships, the company is advancing toward the next phase of clinical and regulatory milestones that will be critical to its long‑term impact in emergency medical care.